Legacy facilities are getting tough to unload

In contrast to the past, it now takes more than a bargain price to attract a buyer for a redundant pharma manufacturing plant. A strong strategic rationale and revenue stream need to be in the mix for the buyer to achieve viability. Executives are walking away from bargain-basement pricing because of missing long-term economics and strategic rationale. Article

Suggested Articles

The cleaning procedures are so poor at a Zydus Cadila plant in India that the FDA says a sampling found 10 different cross-contaminated products.

Mylan is the most recent drugmaker facing the FDA's ire over a tainted API that led to a global recall of "sartan"-based drugs last year.

Merck MSD's $1.2 billion production restructuring has fallen on a site in France, where more than 200 manufacturing and R&D jobs will be swept away.